Cediranib + Olaparib vs Bevacizumab for Recurrent Glioblastoma
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but it does mention that you cannot use certain medications that strongly interact with the trial drugs. You should discuss your current medications with the study team to ensure they are not prohibited.
What data supports the effectiveness of the drug Bevacizumab for recurrent glioblastoma?
Is the combination of Cediranib, Olaparib, and Bevacizumab safe for treating recurrent glioblastoma?
Bevacizumab has been shown to have manageable side effects, with severe treatment-related issues occurring in only a small number of patients. Cediranib has been studied in combination with other treatments for glioblastoma, but specific safety data for the combination of Cediranib, Olaparib, and Bevacizumab is not detailed in the available research.36789
How is the drug combination of Cediranib, Olaparib, and Bevacizumab unique for treating recurrent glioblastoma?
This drug combination is unique because it combines Cediranib, which blocks blood vessel growth in tumors, with Olaparib, a drug that targets cancer cell repair mechanisms, and Bevacizumab, which also inhibits blood vessel growth. This multi-targeted approach aims to enhance treatment effectiveness by attacking the tumor from different angles.910111213
What is the purpose of this trial?
This trial compares two treatments for patients with glioblastoma that has returned. One treatment uses pills that block enzymes needed for tumor growth. The other treatment uses an IV drug that helps the immune system fight cancer and prevents tumors from growing. The goal is to see which treatment works better at stopping the cancer from progressing.
Research Team
Isabel Arrillaga-Romany
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO
Eligibility Criteria
This trial is for adults with recurrent glioblastoma who've had prior radiotherapy and temozolomide treatment. Eligible participants must have stable or decreasing corticosteroid doses, adequate organ function, no severe allergies to the drugs being tested, and not be pregnant or breastfeeding. They should agree to use contraception and have a life expectancy of at least 3 months.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either olaparib and cediranib maleate or bevacizumab. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up at 30 days and then periodically for 3 years.
Treatment Details
Interventions
- Bevacizumab
- Cediranib Maleate
- Olaparib
Bevacizumab is already approved in European Union, United States, Japan, Canada for the following indications:
- Colorectal cancer
- Breast cancer
- Non-small cell lung cancer
- Renal cell carcinoma
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Renal cell carcinoma
- Cervical cancer
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor